On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for the long haul. Cramer’s response was a shrug wrapped around a birthday card. “Only because you told me that can I encourage you to buy it, because this company is losing so much money it may take a lifetime before they make money,” he said.
Why Cramer leaned on the caller’s age
Jackson opened by saying he was turning 23 the next day and was “not looking to sell right now,” framing that lets a host bless a speculative name without endorsing its fundamentals. Cramer took the exit. He named no catalyst, made no case for the pipeline, and then softened: “Let’s have one moment in this show that I’m not angry. Happy birthday.” A young investor absorbing losses over decades is a different animal than a retiree doing the same thing, and Cramer’s approval rested entirely on that time-horizon math.
Voyager is a Cambridge-based clinical-stage gene therapy company focused on neurological diseases. Market cap sits around $213.6 million, trailing EPS is -$1.98, and the company has no approved products. That is the shape of the bet.
The numbers behind the “lifetime” warning
Cramer’s caveat is grounded in the income statement. Voyager reported Q1 FY26 revenue of $2.59 million, which missed the $8.79 million consensus by 70.49% and fell 59.9% year over year. The net loss came in at $27.94 million, with EPS of -$0.47 versus a -$0.53 estimate. Full-year 2025 collaboration revenue with partners including Neurocrine and Novartis dropped from $80 million to $40 million as those deals matured past their research phases. You can see the filing itself in the Q1 press release exhibit.
Cash on hand of $171.66 million is expected to fund operations into 2028, which is real runway. Still, the stock is down 10.94% year to date and 68.64% over ten years, closing at $3.50 on June 30. That decade-long slope is the visual version of Cramer’s warning.
What the bulls actually see
The long thesis is not crazy, and the sell-side agrees. Voyager carries 11 Buy ratings, zero Holds, and zero Sells, with an average analyst target of $14.89. H.C. Wainwright reiterated Buy with a $25.00 target on June 26, 2026.
Moreover, the catalyst calendar explains the enthusiasm. Management has branded 2026 the “Year of Tau” for Alzheimer’s, with FDA IND clearance for VY1706 already in hand as of June 1, 2026 and first-in-human dosing expected in the second half of the year.
Preclinical work showed the drug reduced tau protein by up to 64-75% in non-human primates. A partnered Friedreich’s ataxia program with Neurocrine carries orphan drug designation, and Voyager has flagged up to $2.4 billion in potential non-dilutive milestone payments across its collaborations.
The teaching moment
Cramer’s blessing separated time horizon from thesis. A CFO transition following Nathan Jorgensen’s resignation in May 2026 adds operational noise. Clinical trials fail, dilution is a live risk given the June 9 charter amendment authorizing 240 million shares of common stock, and beta of 1.251 means the ride will be bumpy regardless of drug data. For a 23-year-old sizing a speculative slice of a portfolio, the real question is whether the position is small enough that a zero would not matter. Cramer’s buy call rested entirely on the lifetime caveat.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks